Metagenomi Therapeutics, Inc.
MGX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.81
KIRA · Stoqly’s AI analyst, in plain words
- Metagenomi Therapeutics, Inc. had $25.2M of revenue in fiscal 2025, down 51.8% on the year before.
- Its operating margin was −380.9%, down 210.9 pts: of every 100 in sales, about −381 is left after running the business.
- Metagenomi Therapeutics, Inc. lost $87.9M in fiscal 2025.
- Free cash flow was −$89.5M in fiscal 2025, −354.9% of revenue.
Market cap
$30.3M
P/E
—
Revenue
$25.2M
Net income
−$87.9M
Free cash flow
−$89.5M
Operating margin
−380.9%
Metagenomi Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−51.8%
No. Sales fell 51.8% last year.
Does it make a profit?
−348.5%
No. It lost money last year.
Does profit turn into cash?
−354.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Metagenomi Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Metagenomi Therapeutics, Inc.
- CIK
- 0001785279
Metagenomi Therapeutics, Inc. · MGX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $44.8M | $52.3M | $25.2M |
| Revenue growth | — | 16.8% | −51.8% |
| Operating margin | −175.4% | −170.0% | −380.9% |
| Net income | −$68.3M | −$78.1M | −$87.9M |
| Net margin | −152.5% | −149.3% | −348.5% |
| Diluted EPS | −$20.05 | −$2.36 | −$2.36 |
| Cash | |||
| Cash from operations | −$91.4M | −$109M | −$88.9M |
| Capital expenditure | $9.8M | $3.1M | $0.6M |
| Free cash flow | −$101M | −$112M | −$89.5M |
| FCF margin | −226.2% | −214.5% | −354.9% |
| Share count change | — | 870.1% | 12.8% |
| Debt and strength | |||
| Cash and short-term investments | $271M | $248M | $161M |
| Shareholders' equity | −$136M | $235M | $159M |
| Current ratio | 4.0x | 6.9x | 7.2x |
| Returns and quality | |||
| Return on equity | — | −157.3% | −44.7% |
| Return on tangible equity | — | −33.2% | −55.4% |
| Piotroski F-score | — | 2 | 1 |
| Altman Z'' | 0.1 | 3.1 | −0.6 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Metagenomi Therapeutics, Inc. · MGX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.81 a share, the company is worth $30.3M.
Source: SEC EDGAR XBRL filings (CIK 0001785279). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.